k-RAS mutation and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer
- 1 January 2017
- journal article
- research article
- Published by Medknow in Journal of Cancer Research and Therapeutics
- Vol. 13 (4), 699-701
- https://doi.org/10.4103/jcrt.jcrt_468_17
Abstract
Objective: The aim of this study was to evaluate the relationship between k-RAS gene mutation and the resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with nonsmall-cell lung cancer (NSCLC). Methods: Forty-five pathologies confirmed NSCLC patients who received EGFR-TKI (Gefitinib) treatment were retrospectively included in this study. The mutation of codon 12 and 13, located in exon1 and exon 2 of k-RAS gene were examined by polymerase chain reaction (PCR) and DAN sequencing in tumor samples of the included 45 NSCLC patients. The correlation between Gefitinib treatment response and k-RAS mutation status was analyzed in tumor samples of the 45 NSCLC patients. Results: Eight tumor samples of the 45 NSCLC patients were found to be mutated in coden 12 or 13, with an mutation rate of 17.8% (8/45); the objective response rate (ORR) was 29.7%(11/37) with 1 cases of complete response (CR) and 10 cases of partial response in k-RAS mutation negative patients. Furthermore, the ORR was 0.0% in k-RAS mutation positive patients with none CR. The ORR between k-RAS mutation and nonmutation patients were significant different (P < 0.05). Conclusion: k-RAS gene mutation status was associated with the response of Gefitinib treatment in patients with NSCLC.Keywords
This publication has 8 references indexed in Scilit:
- State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancerTranslational Lung Cancer Research, 2016
- Lung Cancer StatisticsPublished by Springer Science and Business Media LLC ,2015
- Cancer statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point?European Journal of Cancer, 2009
- Anxiety and distress during active surveillance for early prostate cancerCancer, 2009
- Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt PhosphorylationClinical Cancer Research, 2006
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2005